CD38 and systemic lupus erythematosus: Future directions regarding anti-B cell therapies in LN are related to the use of combinations between anti-CD20 and anti-BAFF, the use of anti-CD38 mAb (daratumab) to target long-lived plasma-cells not covered by anti-CD20 mAbs, and the use of CAR T cells that have reported a complete response in six refractory SLE patients, all with LN [65,141,142,143].